Xenon Pharmaceuticals showcases XEN1101 epilepsy program at 35th IEC

Xenon Pharmaceuticals announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress taking place in Dublin, Ireland from September 2-6, 2023. An interim analysis, with a cutoff date of September 22, 2022, of the ongoing X-TOLE open-label extension study demonstrated that treatment with XEN1101 resulted in sustained monthly reduction in seizure frequency from double-blind period baseline, with adverse events consistent with previous results and those seen with other antiseizure medications, and no new safety signals were identified. Newly compiled interim data from the X-TOLE OLE focused on quality-of-life measures as assessed using a validated tool called the Quality of Life in Epilepsy Inventory-31 in the overall OLE group as well as a subgroup that was seizure-free for at least 12 consecutive months at the time of the interim data analysis. The SFG consisted of 29 patients. The overall OLE patient group showed improvements in overall Quality of Life. Clinically important improvements in QOLIE-31 subscales of Seizure Worry, Social Functioning, and Medication Effects were seen across all patients, with even greater improvements in the SFG. The SFG achieved clinically important improvements in all QoL subscales assessed by the QOLIE-31. The improvements in Medication Effects across all patients is notable as this measures the patients’ perception of drug tolerability as well as the benefit of long-term seizure reduction.